Early steroid and anakinra use to manage axicabtagene ciloleucel toxicity reduces the total duration of CRS and ICANS.

Saved in:
Bibliographic Details
Title: Early steroid and anakinra use to manage axicabtagene ciloleucel toxicity reduces the total duration of CRS and ICANS.
Authors: Wang WL; Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA., Lee D; Division of Hematology, Stanford University School of Medicine, Stanford, CA., Cheung E; Department of Pharmacy, Stanford Health Care, Stanford, CA., Jensen A; Quantitative Sciences Unit, Stanford University School of Medicine, Stanford, CA., Rana MS; Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA., Goyal A; Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA., Hamilton M; Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA., Ghalehsari N; Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA., Latchford T; Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA., Scott B; Division of Neurology & Neurological Sciences, Stanford University, Stanford, CA., Mallampet J; Cancer Correlative Science Unit, Stanford University, Stanford, CA., Heng E; Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA., Khan H; Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA., Zarak MS; Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA., Lohman C; Cancer Correlative Science Unit, Stanford University, Stanford, CA., Sahaf B; Cancer Correlative Science Unit, Stanford University, Stanford, CA., Sidana S; Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA., Weng WK; Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA., Smith M; Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA., Bharadwaj S; Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA., Frank MJ; Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA., Miklos DB; Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA., Dahiya S; Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA.
Source: Blood advances [Blood Adv] 2026 May 26; Vol. 10 (10), pp. 3313-3323.
Publication Type: Journal Article
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2473-9537
DOI:10.1182/bloodadvances.2025019031